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background:  A decision support tool (DST) should theoretically help physicians deliver evidence-based, patient-centered care. We examined 
physicians’ changes in bivalirudin use after provision of patient-specific bleeding risk estimates at time of PCI.
methods: In a 9-center study of 9,383 propensity-matched patients treated by 145 physicians, we used hierarchical models to estimate 
physicians’ changes in bivalirudin use, both overall and as a function of bleeding risk, adjusting for center and pre-DST bivalirudin use. We then 
examined physician characteristics (age, sex, country of schooling, interventional cardiology (IC) certification and number of publications) associated 
with change in bivalirudin use.
results: After DST provision, physicians varied significantly on overall bivalirudin use (OR range 0.21-9.34; p 0.006) and use per 1% higher 
bleeding risk (OR range 0.34-1.78; p 0.02) (figure). In adjusted analyses, older age (OR 1.46; CI 1.1-1.95) and IC certification (OR 3.23; CI 1.41-
7.37) were associated with increased overall bivalirudin use, while IC certification was paradoxically associated with decreased bivalirudin use in 
patients at higher bleeding risk (OR 0.58; CI 0.35-0.95).
Conclusion: We observed marked variability in how physicians used bivalirudin in response to a DST. This highlights an opportunity to improve 
rational bivalirudin use by further exploring physician barriers to DSTs as a means of supporting safer, more effective care.
 
